Although Renal Cell Cancer (RCC) is known to be immunogenic, clinical efficacy of various immunotherapeutic approaches remains unsatisfactory. Novel targeted therapies showing cytostatic rather than cytotoxic activity are unable to cure RCC patients. In our studies, we evaluated the therapeutic efficacy of whole-cell vaccine based on irradiated murine RENCA cells genetically modified to secrete designer cytokine-Hyper-IL6 (H6)-comprising IL-6 and soluble IL-6 receptor. An orthotopic RCC model based on a subcapsular implantation of RENCA cells into kidneys of Balb/C mice was employed. The efficacy of RENCA-H6 vaccine was compared with control vaccine (RENCA-wt) in relation to naive (non-immunized) animals. Three sets of vaccination experiments were carried out in a (i) protective, (ii) palliative and (iii) adjuvant (following nephrectomy) setting. The influence of vaccination on survival of RCC-bearing animals was analyzed. Specificity of vaccine-induced immune response was studied using model antigen-GFP. RCC-bearing animals immunized with RENCA-H6 vaccine showed prolonged survival compared with other groups. In palliative and adjuvant settings the survival RENCA-H6-immunized animals exceeded 75%. Administration of RENCA-H6 inhibited formation and recruitment of Treg cells (CD4 þ CD25 þ Foxp3 þ ) and increased maturation of DCs. RENCA tumors in RENCA-H6-vaccinated animals contained large populations of NK cells and activated CD4 þ , CD8 þ T cells. In addition, in mice vaccinated with RENCA-H6 cells large population of CD4 þ and CD8 þ memory cells (CD62Llow) were detected. In the orthotopic RCC model, RENCA-H6 vaccine showed high therapeutic potential, which resulted from modulation of numerous immunological mechanisms.
Introduction
Treatment options for patients with Renal Cell Cancer (RCC) are rapidly expanding and clinical results of traditional, nonspecific immunotherapies based on IFNs, IL-2 or their combinations do not seem to improve any further. With the advent of small molecules for the treatment of metastatic RCC, supported by very recent reports showing their efficacy in clinical settings, 1-3 the interest of oncologists seems to be focusing mostly on molecularly targeted anticancer strategies and antibodybased immunotherapies. 4 However, none of the above mentioned targeted therapeutic approaches has a potential to cure RCC-patients, since the biological effect of targeted agents is rather cytostatic than cytotoxic. 5 Currently, several clinical studies are evaluating the efficacy of various therapies (tyrosine kinase inhibitors, antibodies and vaccines) in the adjuvant treatment of RCC. However, it is still too early to draw any final conclusions about their efficacy.
Cancer vaccines based on irradiated tumor cells deliver a wide spectrum of tumor antigens and may effectively activate anti-tumor immune responses. 6, 7 Immunostimulatory potential of irradiated whole-cell vaccines is strictly dependent on the presence of dendritic cells (DCs) at the site of immunization. DCs phagocytose tumor antigens released from irradiated tumor cells and present them in context of MHC class I and II molecules. In regional lymph nodes DC induce activation of antigen-specific helper and cytotoxic T lymphocytes. 8 Transduction of vaccine cells with genes encoding immunostimulatory molecules can substantially increase their immunogenicity. In several animal models tumor cells modified with interleukin-6 (IL-6) gene efficiently activated anti-tumor immune responses.
9-11 IL-6 acts on cells through IL-6 receptor (IL-6R) complex comprising two membranebound subunits-a (gp80) and b (gp130). The gp130 subunit unlike the gp80 is expressed on every human or animal cell studied so far. 12 A soluble variant of gp80 (sIL-6R) existing in human plasma may form a dynamic complex with IL-6 and then directly stimulate gp130-expressing cells even these completely insensitive to IL-6 because of lack of the gp80. 13 Hyper-IL-6 (H6) is an artificial fusion cytokine comprising IL-6 linked by an artificial linker with the sIL-6R. H6 is a stable protein displaying biological activity in vitro or in vivo 10-1000 fold higher than IL-6/sIL-6R soluble complex. 14 In this study, we have evaluated therapeutic efficacy of a cellular vaccine based on irradiated RENCA cells modified with H6 gene in a murine orthotopic model of RCC. The vaccine displayed significant clinical efficacy in a palliative and adjuvant setting in mice bearing orthotopic RENCA tumors. We have showed that the RENCA-H6 vaccine activated cellular anti-tumor immune mechanisms involving DCs, NK cells and CD4 þ , CD8 þ T lymphocytes. Specifically, it activated maturation of DCs, inhibited formation of T-regulatory lymphocytes (Treg), generated antigen-specific CD8 þ T lymphocytes and induced generation of CD4 þ and CD8 þ memory T cells.
Materials and methods

Animals
In all experiments, female Balb/c F1 mice, 8-12 weeks of age were used. The animals were purchased from the Polish Academy of Sciences (Warsaw/Poland). Animals were kept under constant pathogen-free conditions in rooms with 12-h day/night cycle with unlimited access to food and water. All experiments were performed according to the guidelines approved by the Local Ethical Committee for Animal Research at the University of Medical Sciences, Poznan, Poland.
Tumor cells
Highly immunogenic murine RENCA (renal cell carcinoma) cells were used throughout the study, and in one set of experiments murine sarcoma cells (MethA) were used. Cells were maintained in DMEM medium (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% heatinactivated fetal bovine serum, antibiotics and 2 mM of L-glutamine (all from Invitrogen), hereafter referred to as culture medium. Cells were cultured in 78 cm 2 culture plates at 37 1C in a fully humidified atmosphere of 5% CO 2 /95% air and passaged every 3-4 days.
Adenoviral recombinants
An E1-deleted adenoviral recombinant of the human strain 5 was obtained from Dr Frank Graham (IRBMMerck, Italy). The vector was modified to encode H6 (AdH6). An empty (without transgene) E1-deleted adenoviral vector (AdD7001) was kindly provided by Dr H Ertl (Wistar Institute, Philadelphia, PA). The viruses were propagated and titrated on E1-transfected 293 cells as described previously. 15 
Lentiviral recombinants
Lentiviral vector-encoding GFP protein (Lenti-GFP) was obtained after cotransfection of 293FT packaging cells with 3 vectors-(i) pMD2.G encoding VSV-derived capside, (ii) p8.91 encoding HIV-derived gag and pol genes, and (iii) pWPXL encoding GFP. Following cotransfection 293FT cells were cultured in ex vivo medium (Lonza, Walkersville, MD). Subsequently, 24 and 48 h after cotransfection the culture medium was collected, concentrated using Amicon column (Millipore, Etobicoke, Canada) and used for transduction of RENCA or RENCA-H6 cells. Transduction was carried out on 96-well plate and was repeated three times. Cells with high-level expression of GFP were selected. RENCA-GFP or RENCA-H6-GFP were then used for vaccination experiments.
Tumor vaccine
The gene modified tumor vaccine tested was based on RENCA cells transduced with a cDNA-encoding Hyper-IL-6 (RENCA-H6). RENCA cells were transduced in vitro with a recombinant adenovirus AdH6 or AdD7001. For generation of antigen-specific CD8 þ T lymphocytes RENCA and RENCA-H6 cells were transduced or co-transduced with Lenti-GFP, respectively. Twenty-four hours following transduction cells were irradiated with dose of 80 Gy (Co 60 ). Following irradiation cells were stored in liquid nitrogen until use.
In vivo studies All study groups comprised eight animals. All experiments were repeated three times. To establish an orthotopic tumor model Balb/c mice underwent a kidney subcapsular injection of RENCA cells. Before inoculation of tumor cells, mice were anesthetized with Avertin anesthesia according to a standard protocol. 16 Briefly, mice received i.p. injection (0.7 mg/g) of Avertin working solution (2-2-2 Tribromoethanol diluted in tert-amyl alcohol). Skin of the anesthetized mice at left lumbar region was shaved with an electric shaver. Next, the skin and subcutaneous tissue were cut with a scalpel and the left kidney was exposed. Using a tuberculin syringe 1 Â 10 4 RENCA cells suspended in 10 ml of PBS were injected subcapsularly into the exposed kidney. Finally, the wound was closed with 2-3 surgical stitches. In a set of experiments, 10 days after tumor implantation mice were again anesthetized. The tumor-bearing kidney was exposed and following ligation of renal artery and vein a nephrectomy was performed according to uro-oncological guidelines. In all animals that received subcapsular injections of RENCA cells an autopsy was performed to determine the cause of death.
In all experiments mice were immunized according to two regimes. In a prophylactic setting, mice received a single subcutaneous (s.c.) injection into the left hip of 1 Â 10 6 of RENCA-wt (active control) or vaccine (RENCA-H6) cells suspended in 100 ml of PBS. In a therapeutic and adjuvant setting mice were immunized s.c. five times in 3-day intervals into both hips alternatively with 1 Â 10 6 of RENCA-wt or vaccine cells suspended in 100 ml of PBS. In all experiments survival of mice was monitored twice a week.
In an experiment evaluating the longevity of antitumor immune response induced by immunization with RE-NCA-H6 cells mice cured by adjuvant RENCA-H6 vaccine were used. The experiment was initiated 25 weeks after adjuvant therapy. RENCA-H6-treated mice received s.c. injection of RENCA or Meth-A cells (5 Â 10 5 in 100 ml of PBS). In a control group naive Balb/c mice were injected s.c. with RENCA cells (5 Â 10 5 in 100 ml of PBS). In a second set of experiments tumor-infiltrating lymphocytes were analyzed. Mice were immunized s.c. five times in 3-day intervals with RENCA-wt or RENCA-H6 cells. After 14 days naive mice and mice immunized with RENCA-wt or RENCA-H6 received s.c. injection of 100 ml Matrigel containing 1 Â 10 6 of RENCA cells. Seven days later, mice were killed, and Matrigel nodules were excised, minced, pooled (eight mice per group) and infiltrating lymphocytes were isolated by gradient centrifugation. The single-cell suspension was stained with anti-CD4, anti-CD8, anti-NK1.1 (FITC); anti-CD40, anti-CD43, anti-CD62L, anti-CD69 (PE) monoclonal antibodies (Pharmingen/Becton Dickinson), and analyzed by flow cytometry.
Analysis of anti-tumor cellular responses
Detection of antigen-specific CD8 þ T cells
To evaluate antigen-specific CD8 þ T-cell responses generated by RENCA-H6 vaccine a stable RENCA-GFP cell line was used for preparation of active control and vaccine cells. Mice were immunized s.c. five times in 3-day intervals. On day 20, splenocytes from naive, RENCA-GFP-wt-and RENCA-GFP-H6-immunized mice were isolated and restimulated in vitro with green fluorescent protein (EGFP) 200-208 (HYLSTQSAL) CTL epitopic peptide (0.2 mg/ml) for 7 days. Subsequently, 2 Â 10 6 cells were incubated with antigen presenting cells-labeled Pro5 MHC Pentamer H-2Kd-HYLSTQSAL (Proimmune Ltd, Oxford, UK) at room temperature for 15 min in the dark and washed with PBS. Cells were then incubated in the dark with PE-conjugated anti-mouse CD8 antibody (Pharmingen) at 4 1C for additional 20 min. After completing the staining process, cells were washed again and analyzed immediately using flow cytometry. H]thymidine (1 mCi per well) was added. RENCA cells were co-cultured with restimulated splenocytes at a particular effector/target ratio (1:10, 1:1, 10:1, 100:1) for 6 h. Cells were then harvested and the radioactivity was measured using a scintillation counter.
Cytotoxicity test
Statistical analyses
Survival curves were analyzed by log-rank test. For the comparison of tumor take rate between groups a w 2 -test was used. Differences between samples in immunological tests were analyzed for significance by Student's t-test (two-tailed) or One-way ANOVA test.
Results
Immunization with irradiated RENCA-wt and RENCAAdD7001 cells produces similar prophylactic effect We have decided to compare the prophylactic effect of RENCA-wt and RENCA-AdD7001 cells to determine the most appropriate active control for further experiments. Median survival of naive mice after subcapsular implantation of RENCA cells was 10 weeks (all animals died within 12 weeks). The median survival of RENCAwt immunized animals was 12 weeks (22% survived until the end of experiment), and in RENCA-AdD7001 group 13 weeks (11% of mice survived) (data not shown). There were no statistically significant differences in overall survival (OS) between all experimental groups. Accordingly, in further experiments, irradiated RENCAwt cells were used as active control.
Prophylactic immunization with RENCA-H6 vaccine significantly prolongs survival of orthotopic RCC-bearing animals Prophylactic immunization with RENCA-H6 vaccine performed 14 days before subcapsular implantation of RENCA cells significantly prolonged survival of RCCbearing animals compared with naive and RENCA-wtvaccinated mice (Figure 1a ). Median survival of naive mice was 7.5 weeks (all animals died within 10 weeks). In the RENCA-wt group 25% of animals (two mice) survived until the end of experiments (median survival-10 weeks), and in the RENCA-H6 group 87.5% (seven mice) of animals survived (median survival not reached). There were statistically significant differences in OS between naive and RENCA-wt-immunized mice (P ¼ 0.03) and between RENCA-wt and RENCA-H6 vaccine groups (P ¼ 0.0002). In all succumbed animals autopsy revealed numerous lung metastases and ascites associated with neoplastic infiltration of peritoneum.
Therapeutic immunization with RENCA-H6 vaccine significantly prolongs survival of orthotopic RCC-bearing mice After subcapsular injection of RENCA cells mice were divided into three experimental groups: (i) control (no treatment), (ii) RENCA-wt, (iii) RENCA-H6. Subcutaneous immunization with RENCA-H6 or RENCA-wt cells (five cycles in 3-day intervals) was initiated 24 h following subcapsular implantation of RENCA cells. Both vaccines significantly improved OS of animals bearing orthotopic RENCA tumors (Figure 1b) . RENCA-H6 vaccine cured 87.5% of animals (seven mice) (median survival not reached) and RENCA-wt cured 12.5% of animals (one mice) (median survival-10 weeks). All mice in the control group died within 12 weeks (median survival-7 weeks); RENCA-H6 vs RENCA wt (P ¼ 0.003) and RENCA wt vs no treatment (P ¼ 0.2). In all succumbed animals autopsy revealed numerous lung metastases and ascites associated with neoplastic infiltration of peritoneum.
Adjuvant treatment with RENCA-H6 vaccine significantly prolongs survival of animals following excision of RCC-bearing kidney Ten days after orthotopic implantation of RENCA tumors tumor-bearing kidney was radically excised. Nephrectomized mice were then divided into three experimental groups: control (no therapy), (ii) RENCAwt and (iii) RENCA-H6. Vaccination was initiated 7 days after nephrectomy. Vaccination with RENCA-H6 cells significantly prolonged survival of nephrectomized mice as compared with RENCA-wt and non-immunized groups (P ¼ 0.03) (Figure 1c) . The median survival of non-treated and RENCA-wt vaccinated animals was 7 and 8 weeks, respectively (P ¼ 0.44), and in both groups 25% of animals survived until the end of experiment. In the RENCA-H6 group the median survival was not reached, and 87.5% of animals were alive at the end of the study. In all succumbed animals autopsy revealed numerous lung metastases and ascites associated with neoplastic infiltration of peritoneum.
Immunization with RENCA-H6 vaccine generates a specific, long-lasting anti-tumor immunity To evaluate the specificity of the anti-tumor immune response induced by RENCA-H6 vaccination, mice cured Hyper-IL6-secreting tumor vaccine in mice with RCC PJ Wysocki et al densely infiltrated by memory CD4 þ CD62L low and CD8 þ CD62L low T lymphocytes than in naive or RENCA-wt-immunized animals ( Figure 4) . The Matrigel/RENCA tumors in RENCA-H6-vaccinated animals were infiltrated more intensely by activated CD4 þ 69 þ and CD8 þ CD69 þ T lymphocytes compared with naive and RENCA-wt immunized animals. A significant difference in the infiltration intensity was observed in case of activated CD4 þ CD43 þ and CD8 þ CD43 T cells (Table 1, Figure 5 ). In addition, the percentage of NK cells infiltrating RENCA tumors in RENCA-H6-vaccinated animals was significantly higher than in control or RENCA-wt-immunized mice (Figure 6a ).
RENCA-H6 vaccine augments generation of antigenspecific anti-tumor immune response but does not significantly increase cytotoxicity of splenocytes against RENCA-wt cells As specific immune responses are acknowledged to have a major role in the process of tumor rejection, we decided to evaluate whether immunization with RENCA-H6 vaccine generates antigen-specific CD8 þ T lymphocytes. Mice were immunized s.c. with irradiated RENCA-GFP or RENCA-GFP-H6 cells. Following vaccination splenocytes were collected and specific CD8 þ T cells were stained with GFP pentamer. Vaccination of BALB/c mice with irradiated control RENCA-GPF cells produced 2.26 ± 0.07% of GFP-specific CD8 þ T lymphocytes. However, in mice vaccinated with irradiated RENCA-GFP-H6 vaccine the population of antigen-specific CD8 þ T cells was significantly larger (5.43±0.15%; Po0.0001) (Figure 6b ). In addition, we have analyzed the anti-RENCA cytotoxicity of splenocytes collected from naive, RENCA and RENCA-H6-immunized mice. The splenocytes were restimulated in vitro with irradiated RENCA cells. In the cytotoxicity assay no significant differences were observed between particular groups of animals. However, a slightly higher cytotoxic effect was observed in the case of splenocytes obtained from RENCA-H6 immunized mice (Figure 6c ).
Discussion
There are five major findings of these studies: (i) modification of RENCA cells with H6 gene significantly increased the therapeutic efficacy of the RENCA-based whole-cell vaccine, (ii) RENCA-H6 vaccine significantly extended OS of animals bearing orthotopic RENCA tumors in prophylactic, therapeutic (palliative) and adjuvant settings (iii) RENCA-H6 vaccine induced maturation of DCs and inhibited the engagement of Treg lymphocytes, (iv) RENCA-H6 vaccine augmented generation of antigen-specific CD8 þ T lymphocytes, (v) RENCA-H6 vaccine effectively generated memory CD4 þ and CD8 þ T cells.
We employed an orthotopic model of RCC which in contrast to the subcutaneous model, mimics clinical course of RCC in humans in terms of growth characteristics, metastatic potential and responsiveness to systemic treatment. 17, 18 Other orthotopic tumor models such as prostate or colorectal cancer have also underlined the importance and specificity of an organ-specific microenvironment on tumor biology. 19, 20 We have analyzed the efficacy of RENCA-H6 vaccine in various settings resembling particular clinical conditions observed in RCC patients. The first set of experiments carried out in a prophylactic setting clearly showed that the RENCA-H6 vaccine was able to induce tumor rejection. It also confirmed reports of other groups showing that RENCA wt cells are immunogenic per se Hyper-IL6-secreting tumor vaccine in mice with RCC PJ Wysocki et al and used for immunization may prevent development of RENCA tumors in a small subset of immunized mice. 21 Evaluation of the therapeutic potential of RENCA-H6 vaccine was carried out in palliative and adjuvant settings. In the first series of experiments, we analyzed the efficacy of immunotherapy in mice with established RCC. Analogical situation occurs in patients with locally advanced, inoperable kidney tumor. We have analyzed the therapeutic efficacy of RENCA-H6 vaccination initiated 24 h after subcapsular inoculation of RENCA cells. This particular time-point was chosen owing to our previous studies showing that generation of antitumorspecific immune response in this particular animal model required approximately 14 days, and initiation of vaccination 7 days after inoculation of tumor cells was not able to induce effective immune response. 11 Within few days, the rapidly growing RENCA cells form wellorganized, locally advanced tumors and distant metastases, which may not be responsive to systemic immunotherapy. 22, 23 The therapeutic benefit of RENCA-H6 vaccine seems to be more pronounced when compared with other vaccines or molecular therapies analyzed in preclinical settings in analogical tumor models. 21, 24, 25 For example, Hara et al. 24 showed that vaccination of (five times in 3-day intervals) with irradiated RENCA-wt (control) or RENCA-H6 cells. Fourteen days later viable cells were suspended in Matrigel and implanted s.c. into naive and immunized mice distally from the vaccination site. After 10 days Matrigel nodules were excised, and tumor-infiltrating cells were isolated, stained and analyzed by flow cytometry. Matrigel/RENCA tumors in RENCA-H6-vaccinated mice contained a significantly higher percentage of CD4 þ CD43 þ and CD8 þ CD43 þ T cells compared with RENCA-wt vaccinated animals ( Table 1 ). The CD4 þ CD69 þ and CD8 þ CD69 þ T-cell populations were also larger in RENCA-H6-vaccinated animals, but the difference was insignificant. The data in the figure are representative of three independent experiments. Each experimental group comprised eight animals.
Hyper-IL6-secreting tumor vaccine in mice with RCC PJ Wysocki et al RENCA tumor-bearing mice with RENCA cells expressing IL-12 combined with systemic administration of IL-18 retarded growth of implanted tumors, but could not cure treated animals. Immunization with ex vivo expanded DCs also showed some efficacy in murine RCC models. In a study of Chagnon et al., 26 immunization of RENCA tumor-bearing animals with unmanipulated, ex vivo expanded DCs activated immune mechanisms, but showed only a modest effect on tumor growth. In another study of the same group, prophylactic vaccination with RENCA-pulsed CpG-ODN-treated DCs prevented implantation of RENCA cells in 60% of treated animals and reduced growth of established tumors. 27 Unfortunately, for clinical use all DC-based vaccines must be individualized for each particular patient, are time-consuming and will probably never become an easily accessible off-the-shelf product, which is Hyper-IL6-secreting tumor vaccine in mice with RCC PJ Wysocki et al not the case with the allogeneic, whole-cell tumor vaccines. [28] [29] [30] In the clinical setting, there is a lack of effective adjuvant therapies, which would significantly decrease the risk of tumor relapse following nephrectomy. Therefore, in our study we have evaluated the efficacy of RENCA-H6 vaccine in such a setting. In the orthotopic RCC model nephrectomy could be safely carried out up to 2 weeks following inoculation, however, based on a study of Shibata et al., 31 we have decided to perform surgery 10 days after subcapsular inoculation of tumor cells. The 25% survival rate of non-immunized animals after resection of orthotopic RENCA tumor resembled clinical conditions, where 10-year survival of nephrectomized RCC patients varies between 20 and 50%. [32] [33] [34] [35] Administration of RENCA-H6 vaccine significantly prolonged survival of nephrectomized animals and cured the majority of them, whereas RENCA-wt vaccine did not display any benefit over observation. Again, the therapeutic efficacy of RENCA-H6 vaccine seemed to be higher when compared with other adjuvant systemic therapies evaluated in similar experimental models. 31, 36 Generation of specific antitumor immune response is a multistep process, which engages DCs and NK cells and CD4 þ and CD8 þ T lymphocytes. DCs are responsible for processing and presentation of phagocytosed antigens to T lymphocytes in the context of MHC complex. Single mature DC expressing surface costimulatory molecules is capable of activating from 100 to 3000 T lymphocytes. 37 Intense infiltration by mature DCs of the site of RENCA-H6 administration indicated that H6-stimulated maturation of DCs. We assume that this phenomenon might be partially responsible for the efficacy of RENCA-H6 vaccine. Our previous studies showed that anti-tumor activity of H6 depends on GM-CSF expression, which is a crucial factor responsible for maturation of DCs. 38 In addition, it is known that DCs exposed to IL-6 prime T cells against cryptic determinants and broaden the spectrum of target antigens, which may be recognized by effectory T cells. 39 Accordingly, it is highly possible that H6-secreted at the site of vaccination stimulated DCs to present cryptic antigens.
On the other hand CD4 þ CD25 þ Foxp3 þ T-regulatory lymphocytes (Treg) may directly suppress activation and maturation of DCs. 40 Transformation of naive CD4 þ CD25-T lymphocytes into Treg is facilitated by TGF-b. 41, 42 The site of RENCA-wt cells administration was densely infiltrated by CD4 þ CD25 þ Foxp3 þ cells. This phenomenon may be attributable to the TGF-b, because wild-type RENCA cells secrete significant amounts of this cytokine. 43 In addition, RENCA tumors may attract naturally occurring Treg via secretion of various chemokines. 44 In contrast there were only few Tregs infiltrating RENCA-H6 administration site. Accordingly, it is possible that H6 directly impairs recruitment and local generation of Tregs. In a recent study of Chen et al., 45 inhibition of IL-6 trans-signaling by IL-6R blockade led to a dramatic increase in the absolute number of Tregs. In addition, Dominitzki et al. 46 have shown that trans-signaling via the soluble IL-6R abrogates induction of Foxp3 in naive CD4 þ CD25À T cells by augmenting expression of the TGF-b signaling inhibitor SMAD7. As H6 displays even much higher in vivo biological activity than the IL-6-sIL-6R complex, 14 we assume that H6 secreted by vaccine cells could similarly impair generation of Tregs in immunized animals.
Efficient rejection of RENCA tumors following vaccination requires both helper and cytotoxic antigen-specific T lymphocytes. 21, 24, 47 Indeed, in mice immunized with RENCA-H6 vaccine subcutaneous RENCA tumors were densely infiltrated by activated CD4 þ and CD8 þ T lymphocytes. In our previous studies in a murine model of malignant melanoma we have shown that vaccination with H6-modified cells induced Th1 and Tc1 immune responses characterized by the presence of antigenspecific, IFNg-secreting CD4 þ and CD8 þ T lymphocytes. 48 In this study, immunization with RENCA-H6 cells resulted in generation of antigen-specific CD8 þ T lymphocytes. IFN-g secreted by CD8 þ and CD4 þ T cells upon stimulation with H6 may induce upregulation of MHC class II complex in RENCA cells. 49 This phenomenon results in an enhanced presentation of RENCA antigens to specific CD4 þ T lymphocytes. Cytotoxic potential of splenocytes obtained from naive or immunized (RENCA-wt or RENCA-H6) mice did not differ significantly between particular groups. It may indicate that direct killing of tumor cells does not represent the crucial anti-tumor mechanism induced by H6-expressing vaccine and that some other mechanisms for example, inhibition of angiogenesis may be involved in rejection of RENCA tumors. Indeed, several studies showed that IFNg secreted by CD4 þ and CD8 þ T cells possessed a strong anti-angiogenic potential, which effectively impaired tumor-induced angiogenesis. 50, 51 In addition, immunization with RENCA-H6 vaccine generated larger populations of CD4 þ CD62L low and CD8 þ CD62L low T cells compared with RENCA-wt vaccine. Cells with low expression of CD62L antigen represent populations of memory T lymphocytes, 52, 53 however, the level of CD62L expression does not correlate with their activity. 54 Specific memory T cells induced in course of vaccination with RENCA-H6 in adjuvant setting mediated the rejection of s.c. RENCA tumors by long-term survivors.
We have shown that our tumor vaccine based on RENCA cells transduced with Hyper-IL6 gene possessed a significant antitumor potential and significantly improved overall survival of RCC-bearing animals. Administration of RENCA-H6 vaccine activated distinct anti-tumor immune mechanism. However, the overall therapeutic efficacy of RENCA-H6 vaccine might have activated some other, non-immune antitumor mechanisms, owing to the very wide spectrum of biological activity of Hyper-IL6.
